Eosinophilic airway diseases: basic science, clinical manifestations and future challenges
Research output: Contribution to journal › Review › Research › peer-review
Standard
Eosinophilic airway diseases : basic science, clinical manifestations and future challenges. / Janson, Christer; Bjermer, Leif; Lehtimäki, Lauri; Kankaanranta, Hannu; Karjalainen, Jussi; Altraja, Alan; Yasinska, Valentyna; Aarli, Bernt; Rådinger, Madeleine; Hellgren, Johan; Lofdahl, Magnus; Howarth, Peter H.; Porsbjerg, Celeste.
In: European Clinical Respiratory Journal, Vol. 9, No. 1, 2040707, 2022.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Eosinophilic airway diseases
T2 - basic science, clinical manifestations and future challenges
AU - Janson, Christer
AU - Bjermer, Leif
AU - Lehtimäki, Lauri
AU - Kankaanranta, Hannu
AU - Karjalainen, Jussi
AU - Altraja, Alan
AU - Yasinska, Valentyna
AU - Aarli, Bernt
AU - Rådinger, Madeleine
AU - Hellgren, Johan
AU - Lofdahl, Magnus
AU - Howarth, Peter H.
AU - Porsbjerg, Celeste
N1 - Publisher Copyright: © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Eosinophils have a broad range of functions, both homeostatic and pathological, mediated through an array of cell surface receptors and specific secretory granules that promote interactions with their microenvironment. Eosinophil development, differentiation, activation, survival and recruitment are closely regulated by a number of type 2 cytokines, including interleukin (IL)-5, the key driver of eosinophilopoiesis. Evidence shows that type 2 inflammation, driven mainly by interleukin (IL)-4, IL-5 and IL-13, plays an important role in the pathophysiology of eosinophilic airway diseases, including asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome. Several biologic therapies have been developed to suppress type 2 inflammation, namely mepolizumab, reslizumab, benralizumab, dupilumab, omalizumab and tezepelumab. While these therapies have been associated with clinical benefits in a range of eosinophilic diseases, their development has highlighted several challenges and directions for future research. These include the need for further information on disease progression and identification of treatable traits, including clinical characteristics or biomarkers that will improve the prediction of treatment response. The Nordic countries have a long tradition of collaboration using patient registries and Nordic asthma registries provide unique opportunities to address these research questions. One example of such a registry is the NORdic Dataset for aSThmA Research (NORDSTAR), a longitudinal population-based dataset containing all 3.3 million individuals with asthma from four Nordic countries (Denmark, Finland, Norway and Sweden). Large-scale, real-world registry data such as those from Nordic countries may provide important information regarding the progression of eosinophilic asthma, in addition to clinical characteristics or biomarkers that could allow targeted treatment and ensure optimal patient outcomes.
AB - Eosinophils have a broad range of functions, both homeostatic and pathological, mediated through an array of cell surface receptors and specific secretory granules that promote interactions with their microenvironment. Eosinophil development, differentiation, activation, survival and recruitment are closely regulated by a number of type 2 cytokines, including interleukin (IL)-5, the key driver of eosinophilopoiesis. Evidence shows that type 2 inflammation, driven mainly by interleukin (IL)-4, IL-5 and IL-13, plays an important role in the pathophysiology of eosinophilic airway diseases, including asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome. Several biologic therapies have been developed to suppress type 2 inflammation, namely mepolizumab, reslizumab, benralizumab, dupilumab, omalizumab and tezepelumab. While these therapies have been associated with clinical benefits in a range of eosinophilic diseases, their development has highlighted several challenges and directions for future research. These include the need for further information on disease progression and identification of treatable traits, including clinical characteristics or biomarkers that will improve the prediction of treatment response. The Nordic countries have a long tradition of collaboration using patient registries and Nordic asthma registries provide unique opportunities to address these research questions. One example of such a registry is the NORdic Dataset for aSThmA Research (NORDSTAR), a longitudinal population-based dataset containing all 3.3 million individuals with asthma from four Nordic countries (Denmark, Finland, Norway and Sweden). Large-scale, real-world registry data such as those from Nordic countries may provide important information regarding the progression of eosinophilic asthma, in addition to clinical characteristics or biomarkers that could allow targeted treatment and ensure optimal patient outcomes.
KW - asthma
KW - chronic rhinosinusitis with nasal polyps
KW - Eosinophil
KW - eosinophilic granulomatosis with polyangiitis
KW - hypereosinophilic syndrome
KW - Nordic
KW - NORDSTAR
KW - real-world
KW - registry
KW - severe asthma
U2 - 10.1080/20018525.2022.2040707
DO - 10.1080/20018525.2022.2040707
M3 - Review
C2 - 35251534
AN - SCOPUS:85126185647
VL - 9
JO - European Clinical Respiratory Journal
JF - European Clinical Respiratory Journal
SN - 2001-8525
IS - 1
M1 - 2040707
ER -
ID: 313766996